RBC Capital Markets on Thursday upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Sector Perform, arguing that the ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $467.35, marking a +1.35% move from the previous day.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

According to TipRanks.com, Schock is a 2-star analyst with an average return of 2.9% and a 53.3% success rate. Schock covers the Healthcare sector, focusing on stocks such as InfuSystem Holdings, ...

Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years ...

Vertex Pharmaceuticals' leading cystic fibrosis franchise still looks promising. It also has a couple of exciting newer launches, and could land another one. Shares of the large drugmaker could still ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs and ...

PROVIDENCE, R.I. (WPRI) — Vertex Pharmaceuticals is laying off 125 workers in Rhode Island. According to a Worker Adjustment Retraining Notification (WARN) letter sent by Vertex to the R.I. Department ...